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Known major mutations such as BRCA1/2 and TP53 only cause a small proportion of heritable breast cancers. Co-dominant
genes of lower penetrance that regulate hormones have been thought responsible for most others. Incident breast cancer
cases in the identical (monozygotic) twins of representative cases reﬂect the entire range of pertinent alleles, whether acting
singly or in combination. Having reported the rate in twins and other relatives of cases to be high and nearly constant over
age, we now examine the descriptive and histological characteristics of the concordant and discordant breast cancers occurring
in 2310 affected pairs of monozygotic and fraternal (dizygotic) twins in relation to conventional expectations and hypotheses.
Like other ﬁrst-degree relatives, dizygotic co-twins of breast cancer cases are at higher than usual risk (standardised incidence
ratio (SIR)=1.7, CI=1.1–2.6), but the additional cases among monozygotic co-twins of cases are much more numerous, both
before and after menopause (SIR=4.4, CI=3.6–5.6), than the 100% genetic identity would predict. Monozygotic co-twin
diagnoses following early proband cancers also occur more rapidly than expected (within 5 years, SIR=20.0, CI=7.5–53.3).
Cases in concordant pairs represent heritable disease and are signiﬁcantly more likely to be oestrogen receptor-positive than
those of comparable age from discordant pairs. The increase in risk to the monozygotic co-twins of cases cannot be attributed
to the common environment, to factors that cumulate with age, or to any aggregate of single autosomal dominant mutations.
The genotype more plausibly consists of multiple co-existing susceptibility alleles acting through heightened susceptibility to
hormones and/or defective tumour suppression. The resultant class of disease accounts for a larger proportion of all breast
cancers than previously thought, with a rather high overall penetrance. Some of the biological characteristics differ from those
of breast cancer generally.
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The prevalence of familial cases indicates that about 10% of all
breast cancers are heritable (Rowell et al, 1994), but major muta-
tions such as BRCA1, BRCA2, and TP53 can only be a minority
of these (Cui et al, 2001b; Peto et al, 1999); familial cases are
especially prominent before menopause (Pharoah et al, 1997).
The genes responsible for most heritable breast cancers are
unidentiﬁed. Due to the role of hormones in breast cancer risk,
genes regulating hormone production or transport have been
emphasized. Those that are common and of low penetrance have
been singled out (Ford et al, 1995; Feigelson et al, 1996), and an
autosomal mode of inheritance is thought likely (Williams and
Anderson, 1984; Newman et al, 1988; Iselius et al, 1991; Cui
et al, 2001a; Claus et al, 1991; Chen et al, 1995; Bishop et al,
1988).
Although BRCA1 tumours are less likely to express oestrogen
receptors (Armes et al, 1999; Phillips, 2000), heritable tumours
seem histologically heterogeneous (Lakhani et al, 2000). Attempts
to separate non-heritable from heritable breast cancer cases have
relied on family history, and even when based on ﬁrst-degree rela-
tives, this criterion is unsatisfactory. Many genetically determined
cases give a false negative family history (Cui and Hopper, 2000),
and false positive histories occur by chance, especially in large
families. Even BRCA1/2 mutations do not correlate particularly
well with family history (Hopper et al, 1999). Moreover, true
multiplex families mostly reﬂect conditions of high penetrance.
Cases caused by gene combinations, recessive genes, or genes of
low penetrance are less likely to have affected relatives. Thus
neither the true proportion of breast cancers that are heritable
nor the proportionate role of speciﬁc genetic determinants is actu-
ally known.
Adult twins are ordinary persons who share a nearly identical
early environment as well as about half (dizygotic) or all
(monozygotic) of the genome. Monozygotic (MZ) twinning is
not known to be appreciably inﬂuenced by either genetic or
environmental factors. Therefore the cases of disease among
MZ twins can be presumed genetically representative of the
population, and disease-concordant pairs must necessarily share
all heritable determinants. We have reported (Peto and Mack,
2000) that the subsequent annual incidence in the MZ co-twins
of breast cancer cases is not only extremely high (1300:100000)
but relatively constant throughout life, just as it is in the
contra-lateral breasts of cases (Robbins and Berg, 1964; Hislop
et al, 1984; Harvey and Brinton, 1985). Here we assess in more
detail the breast cancers occurring in the MZ and DZ twins of
representative breast and other cancer cases (Mack et al, 2000),
report the unique descriptive and histological characteristics of
concordant twin breast cancer cases, and examine current
hypotheses in light of the ﬁndings.
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From 1980–91, 17245 affected twin pairs responded to advertise-
ments seeking ‘twins with cancer and other chronic diseases’ in the
non-classiﬁed pages of major periodicals serving English-speaking
North America (Mack et al, 2000). Each pair was contacted by tele-
phone and asked to provide details of their age, zygosity, and
diagnosis.
Among the 6325 female twin pairs with cancer were 2562
probands with breast cancer, including the members of 200 MZ
and 109 dizygotic (DZ) concordant pairs. More than 95% were
non-Latino and white, and we have assessed their representiveness
by computing the estimated prevalence of breast cancer cases
among living white adult twins in North America (Mack et al,
2000), using cohort-speciﬁc birth rates (Elwood, 1973; Jeanneret
and MacMahon, 1962; Statistics NCfH, all years), life tables (Klein-
man et al, 1991), and site-speciﬁc cancer incidence (Gaudette, 1992;
Hankey and Percy, 1992) and survival (Hankey et al, 1993). We
also compared the unaffected co-twins to population-based samples
of healthy US residents (Mack et al, 2000). We estimate that we
identiﬁed over a third of all MZ twin breast cancer cases occurring
before age 60 in the period. Our ascertainment was less complete
for twin cases who were DZ, over 65 at diagnosis, or discordant
for disease at the time of ascertainment, but neither region,
community characteristics, interval since diagnosis, nor outcome
appeared to inﬂuence ascertainment (Mack et al, 2000).
Medical records were sought to verify diagnoses, and were
obtained for 80% of the breast cancer cases. Of those, 94% were
reported to be invasive. Tumour specimens were requested for
review (successfully in 65%) and cases were classiﬁed according
to standard cancer registry practice (Percy et al, 1990). When diag-
nostic and classiﬁcational errors were found to be negligible among
the ﬁrst 805 specimens reviewed, the practice was discontinued.
Twins’ perception of their zygosity, repeatedly shown to be over
90% accurate by others (Kasriel and Eaves, 1976; Torgersen,
1979) as well as ourselves (Deapen et al, 1992; Kumar et al,
1993), were nearly all in agreement, and those in disagreement
were excluded from zygosity-speciﬁc results.
All twins were followed prospectively by mail to identify deaths
and new diagnoses. National age, period, and neoplasm-speciﬁc
incidence rates (Hankey and Percy, 1992), were applied to the
person-years of follow-up to estimate the expected number of new
cases. The indirectly age-adjusted standardised incidence ratio of
observed to expected cases (SIR), was calculated by age, sex, and
zygosity, as was the incidence rate/100000 person-years. Since inclu-
sion of some co-twins preferentially identiﬁed as cases in retrospect
at original ascertainment may introduce bias, pairs already concor-
dant at ascertainment were excluded. Thus analysis was restricted to
the initially unaffected 2310 co-twins of breast cancer cases and 3628
co-twins of other cancer cases. Events occurring between ascertain-
ment of the affected pair and the date of last contact, always prior to
February 1, 1993, were recorded. For MZ twins of breast cancer
cases, the average length of follow-up was 4.8 (95% CL 4.6–5.0)
years, with 16.4 and 49.0% followed for one year or less and 5 or
more years respectively. For DZ twins of breast cancer cases, the
average follow-up was for 4.6 (95% CL 4.4–4.8) years, with 14.9
and 48.8% followed for 1 or less and 5 or more years respectively.
For concordant pairs (including those concordant at ascertain-
ment) and a sample of MZ discordant pairs, additional efforts
were made to obtain representative tumour blocks from the initial
breast cancer surgery. Using the parafﬁn-embedded tissue from 196
cases from concordant pairs and 190 cases from MZ discordant
pairs, a single pathologist (MP) blindly reviewed the histology of
the tumours, and assessed the prevalence of oestrogen receptors
(ER), progestin receptors (PR), p53, and HER-2/neu expression
by immunohistochemical methods. HER2/neu membrane protein
was scored as low, over-expressed, or highly over-expressed, and
considered positive under either of the latter alternatives. ER, PR,
and p53 nuclear proteins were scored by prevalence of cells staining
at each of three levels of intensity. For the present purpose a
tumour was considered to be positive if 10% or more of the cells
stained positively. Multivariate linear regression analysis (SAS Proc
GLM) was used to control for age at diagnosis when comparing the
frequency of positive tumour markers among the twin pair subsets.
Religious preference was obtained by questionnaire from the
twins comprising 1944 affected pairs. We located and obtained
blood samples from 27 surviving cases belonging to 19 multiplex
Jewish families in which diagnoses occurred before 50. Three
common Ashkanazi mutations: two BRCA1 (185delAG, exon 2,
and 5382insC, exon 20) and one BRCA2 (6174delT, exon 11) were
tested (Ursin et al, 1997).
RESULTS
One hundred and forty-eight cancers of the breast in the initially
healthy co-twins of cancer cases were diagnosed during the period
of prospective follow-up, of whom 99 (22 DZ and 77 MZ) occurred
among the co-twins of breast cancer cases. Table 1 describes the
occurrence of these prospectively identiﬁed cancers in terms of inci-
dence and standardised incidence ratio according to zygosity, age and
site of proband diagnosis, and person-years of follow-up.
Breast cancer incidence in the co-twins of non-breast cancer
cases increased with age past menopause as expected, and for all
ages combined, no substantial or signiﬁcant risk attributable to
twin status was found. Marginal excesses of malignancy other than
breast cancer occurred in MZ, but not DZ, twins of breast cancer
cases diagnosed before age 50. The appearance of additional breast
cancer cases among the initially healthy co-twins of breast cancer
cases was substantial and signiﬁcant. Among the DZ co-twins,
the 22 new cases represent an unstable annual age-speciﬁc inci-
dence ranging from 227 to 689:100000, reﬂecting a statistically
signiﬁcant age-adjusted SIR of 1.7, a 70% excess over expected.
Among the MZ co-twins, the 77 new cases reﬂect an annual inci-
dence ranging from 1144 to 1439:100000, and an overall SIR of
4.4, a 340% excess over expected, and one as high as 7.1 before
40 years of age. Figure 1 compares the age-speciﬁc rates in the
MZ co-twins to the highest and lowest North American popula-
tion-based rates (Parkin et al, 1992). If the MZ proband had
bilateral breast cancer, especially likely to represent heritable disease
(Bernstein et al, 1992; Hislop et al, 1984), the SIR for the co-twins
showed a similar gradient with age and was even higher overall at
7.3, reﬂecting an attributable excess of 630%. Overall, 23% and 3%
of the concordantly affected MZ pairs had one and more than one
affected ﬁrst degree relative respectively (data not shown).
In Table 2, the appearance of breast cancer in co-twins is
described according to the interval following the proband’s cancer
diagnosis. Within the ﬁrst ﬁve years after the diagnosis in a
proband younger than age 40, the SIR among MZ co-twins was
many times higher than expected, and the magnitude fell in inverse
proportion to the time elapsed. This tendency was not apparent
among DZ co-twins or after diagnoses in older probands.
Overall, 8.6% of the concordant and 7.6% of the discordant MZ
pairs identiﬁed themselves as Jewish. Among those ﬁrst diagnosed
before age 50, 10.1% of those concordant and 6.8% of those
discordant did so. Thus being Jewish increased the risk of concor-
dant diagnoses by a factor of 1.3 overall, and 1.5 premenopausally.
Of the 19 tested multiplex Jewish families with at least one preme-
nopausal diagnosis, BRCA1 mutations were found in 4, and a
BRCA2 mutation in 1.
More than 97% of the tissue samples from MZ twins (concor-
dant and discordant) showed evidence of invasiveness (Table 3)
Although a slightly higher proportion of lobular tumours occurred
among the MZ concordant pairs, no signiﬁcant difference by histo-
logic subtype (ductal, lobular, ductal in-situ) was found, and only a
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PR and ER positivity were signiﬁcantly more common among
older cases, and ER positivity was signiﬁcantly higher among cases
from concordant than among those from discordant pairs, espe-
cially after age 50 (Figure 2). After age 50, HER2/neu and p53
were more common among cases from concordant than discordant
MZ pairs; the former difference was signiﬁcant and the latter nearly
so. Biomarker combinations were examined, and concordant cases
were more likely to be ER+PR+ (age-adjusted preva-
lence=54.1%1.7% MZ, 55.07.2% DZ) than were discordant cases
(41.30.8% MZ), but the difference could be explained by chance.
No excess prevalence of ER-p53+ concordant cases was found
(concordant MZ 13.21%, DZ 12.84.6%, and discordant MZ
13.914.4%).
DISCUSSION
Since DZ co-twins experience a level of risk no higher than
that of other ﬁrst-degree relatives generally (Brinton et al,
1982; Claus et al, 1990; Houlston et al, 1992; Olsen et al,
1999; Thompson, 1994; Tulinius et al, 1992), despite sharing
a substantially more similar environment, the very high inci-
dence among representative MZ co-twins of breast cancer
cases (Table 1) serves to verify the substantial heritability of this
disease (Easton et al, 1993; Eby et al, 1994; Lichtenstein et al,
2000; Thompson, 1994). Moreover, our estimate of incidence
in MZ co-twins is probably an underestimate. It is based solely
on prospective follow-up, and a number of rapidly concordant
MZ pairs, i.e. those with co-twin cases occurring soon after
the proband diagnosis but before ascertainment, were preferen-
tially excluded to eliminate bias. The similarity of the
observed high and constant age-speciﬁc rate to that in the
contralateral breasts of breast cancer cases (Harvey and Brinton,
1985; Robbins and Berg, 1964) provides additional evidence that
bilateral disease is largely attributable to the genome rather than
the personal environment.
No more than a small minority of heritable co-twin cases can be
attributed to BRCA1/BRCA2 or other known major mutations.
More than three-fourths of the additional cases among MZ co-
twins occur after 40 (Table 1), whereas most BRCA1/2 cases occur
before that age (Ford et al, 1998). While 23% of the concordantly
affected MZ pairs had one affected ﬁrst degree relative, only 3%
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Table 1 Incidence of breast cancer and other cancer in the twins of North American cases of breast and other cancer, prospective ascertainment
a, female
like sex pairs by zygosity
DZ like sex female pairs MZ female pairs
Incidence Incidence
Age at ﬁrst /100 000 /100 000
diagnosis Pairs
b Person-years Exp
c Obs Person-years SIR
d (CI) Pairs
b Person-years Exp
c Obs Person-years SIR
d (CI)
Non-breast cancer in the twins of non-breast cancer cases
550 years 886 3992.1 11.7 10 250.5 0.9 (0.4–1.6) 1238 5524.7 14.2 22 398.2 1.5 (1.0–2.3)
50+ years 583 2374.0 19.6 22 926.7 1.1 (0.7–1.7) 812 3304.3 27.8 25 756.6 0.9 (0.6–1.3)
Breast cancer in the twins of non-breast cancer cases
530 years 357 1685.7 1.3 2 118.6 1.5 (0.1–5.7) 514 2256.7 1.8 3 132.9 1.7 (0.3–4.9)
30–39 years 255 1207.3 2.3 4 331.3 1.7 (0.5–4.5) 385 1855.8 3.2 2 107.8 0.6 (0.1–2.3)
40–49 years 281 1258.0 3.6 5 397.5 1.4 (0.4–3.3) 367 1699.3 4.7 7 411.9 1.5 (0.6–3.1)
50–59 years 313 1416.0 4.9 4 282.5 0.8 (0.2–2.1) 410 1909.8 6.6 13 680.7 2.0 (1.0–3.4)
60+ years 298 1093.6 4.5 3 274.3 0.7 (0.1–2.0) 443 1607.6 6.6 6 373.2 0.9 (0.3–2.0)
Total 1509 6660.6 16.5 18 270.2 1.1 (0.6–1.7) 2119 9329.2 23.0 31 332.3 1.3 (0.9–1.9)
Non-breast cancer in the twins of non-breast cancer cases
550 years 536 2434.3 11.2 10 410.8 0.9 (0.4–1.6) 742 3579.2 16.2 23 642.2 1.4 (0.9–2.1)
50+ years 452 2062.2 18.7 16 775.9 0.9 (0.5–14) 698 2937.3 26.5 27 919.2 1.0 (0.7–1.5)
Breast cancer in the twins of non-breast cancer cases
530 years 28 131.6 0.1 0 0 0 36 162.5 0.2 2 1230.8 10.0 (2.5–40.0)
30–39 years 154 743.9 1.4 4 537.7 2.9 (1.1–7.4) 238 1149.9 2.1 15 1304.5 7.1 (4.3–11.8)
40–49 years 335 1451.6 4.0 10 688.9 2.5 (1.3–4.6) 400 1835.2 5.0 21 1144.3 4.2 (2.7–6.4)
50–59 years 261 1320.6 4.5 3 227.2 0.7 (0.2–2.1) 371 1667.4 5.6 24 1439.4 4.3 (2.9–6.4)
60+ years 192 737.3 3.0 5 678.2 1.7 (0.7–4.0) 295 1081.6 4.4 15 1386.8 3.4 (2.0–5.6)
Total 970 4385.0 13.0 22 501.7 1.7 (1.1–2.6) 1340 5896.6 17.3 77 1305.8 4.4 (3.6–5.6)
Bilateral probands 61 369.8 1.2 2 540.8 1.7 (0.4–6.7) 73 375.7 1.1 8 2129.4 7.3 (3.6–14.5)
aProspective ascertainment = follow-up between ﬁrst notiﬁcation and 31 January, 1993.
bExcluded pairs: imprecise age or date of diagnosis, death or outcome diagnosis before
entry, non-validated diagnosis.
cBased on SEER age, sex and site-speciﬁc incidence rates applied to person-years of folow-up (Hankey and Percy, 1992).
dStandard Incidence
Ratio.
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Figure 1 Age-speciﬁc Incidence of breast cancer in identical co-twins of
breast cancer cases compared to that in highest and lowest risk North
American populations (42).
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Hopper, 2000). Jewish women are at high risk from disease caused
by major mutations. Although the risk to a woman from a Jewish
multiplex family (Egan et al, 1996) or a Jewish family with a
BRCA1/2 mutation (Fodor et al, 1998) is increased by a factor of
3–4, and although Jewish women are also at higher risk from
additional breast cancer risk factors (Swift et al, 1987), we found
that a Jewish MZ co-twin’s risk of becoming affected was increased
only marginally more than that to Jewish women generally (Mack
et al, 1985; Warner et al, 1999). Even among multiplex Jewish
families with early cases, we could identify only a few with
BRCA1/2 mutations. Moreover, whereas BRCA1/2 neoplasms tend
to be ER-, especially in connection with P53 mutations, and tend
to include an excess of the medullary histological type (Lakhani,
1999; Phillips, 2000), the tumours in these concordant MZ twins
were not medullary, and tended to be ER+, without a link to
P53 mutations (Table 3, Figure 2).
The proportion of MZ co-twin cases attributable to genetic
determinants is roughly 77% (4.4-1)/4.4) (Table 1), indicating that
MZ twin breast cancer-concordant cases, unlike familial cases
generally, are much more likely than not to represent heritable
cases. Based on the observed age-speciﬁc incidence in the co-twins
of MZ cases (Table 1), the cumulative risk among those surviving
to age 75 would be at least 44.5%, indicating that only a fraction of
the minority with heritable disease remain discordant. MZ twin
breast cancer-discordant cases can therefore be presumed to repre-
sent disease which is not strongly heritable. Material from breast
cancer concordant and discordant MZ twin pairs clearly offers
the best opportunity available to compare cases that are heritable
with those that are not.
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Table 2 Occurrence of female breast cancer in the twins of female breast cancer cases according to zygosity, age at ﬁrst diagnosis and elapsed interval
after proband diagnosis, prospective ascertainment
a
DZ like sex female pairs MZ female pairs
Age at ﬁrst diagnosis
Interval after ﬁrst Dx Pairs
b Person-years Exp
c Obs SIR
d (CI) Pairs
b Person-years Exp
c Obs SIR
d (CI)
540 years 182 274
55 years 222.5 0.2 0 0 325.1 0.2 4 20.0 (7.5–53.3)
5–9 years 251.5 0.3 2 6.7 (1.7–26.6) 372.9 0.4 6 15.0 (6.7–33.4)
10+ years 401.4 1.1 2 1.8 (0.4–7.3) 614.5 1.6 7 4.4 (2.1–9.2)
40+ years 788 1066
55 years 1010.2 2.9 7 2.4 (1.2–5.1) 1528.4 4.4 12 2.7 (1.5–4.8)
5–9 years 1073.0 3.4 4 1.2 (0.4–3.1) 1382.2 4.4 24 5.4 (3.6–8.1)
10+ years 1426.1 5.3 7 1.3 (0.6–2.8) 1673.7 6.1 24 3.9 (2.6–5.9)
aProspective ascertainment = follow-up between ﬁrst notiﬁcation and 31 January, 1993.
bExcluded pairs: imprecise age or date of diagnosis, death or outcome diagnosis before
entry, non-validated diagnosis.
cBased on SEER age, sex and site-speciﬁc incidence rates applied to person-years of folow-up (Hankey and Percy, 1992).
dStandard Incidence
Ratio.
Table 3 Prevalence of selected histologic characteristics of breast cancers from twins according to age, zygosity and
concordancy
Tumours in cases from Tumours in cases from
concordant pairs
b discordant pairs
Tumour MZ DZ MZ
characteristics % (95% C.L.) % (95% C.L.) % (95% C.L.)
N 114 43 190
Histology
DCIS 2.5 (0–6.1) 11.4 (5.6–17.2) 2.9 (0–5.6)
IDC 77.4 (70.4–84.4) 81.7 (70.3–93.0) 87.0 (81.6–92.3)
ILC 15.3 (9.7–20.8) 4.1 (0–13.1) 7.7 (3.4–11.9)
All Ages of Dx
a
ER+ 66.0 (57.3–74.8) 67.8 (53.5–82.2) 50.1 (43.4–56.8)
PR+ 62.0 (52.9–71.0) 58.7 (43.9–73.6) 52.8 (45.8–59.8)
p53+ 26.4 (18.5–34.3) 22.9 (9.9–35.9) 22.4 (16.3–28.5)
HER2/neu+ 22.8 (15.8–29.9) 9.2 (0–20.8) 16.5 (11.0–22.0)
Dx550
a
N3 7 1 47 9
ER+ 42.3 (26.9–57.7) 41.1 (15.5–66.8) 42.3 (31.9–52.7)
PR+ 48.0 (32.4–63.5) 52.4 (27.3–77.4) 44.8 (34.3–55.3)
p53+ 25.0 (10.6–39.4) 23.2 (0–47.2) 25.3 (15.5–35.0)
HER2/neu+ 13.2 (1.6–24.8) 5.5 (0–24.2) 17.0 (9.2–25.0)
Dx550
a
N 77 29 111
ER+ 80.0 (69.6–90.5) 83.8 (66.8–100) 53.2 (44.7–61.8)
PR+ 70.2 (59.3–81.1) 64.4 (46.1–82.8) 56.7 (47.5–65.9)
p53+ 27.4 (19.5–35.3) 24.8 (11.7–37.8) 19.6 (11.6–27.5)
HER2/neu+ 28.3 (19.5–37.1) 13.7 (0–28.5) 14.8 (7.3–22.2)
Bold values indicate where statistically signiﬁcant differences occurred between groups.
aAdjusted for age as a continuous variable.
bOne
case per pair included in analysis. Among pairs with tissue available from both members, the ﬁrst diagnosed case was used.
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proportion of the total burden than conventionally thought. In
Scandinavia (Lichtenstein et al, 2000), 14% of MZ twin pairs were
found to be concordant. However, the population-based ascertain-
ment ignored discordant mortality and necessarily excluded
substantial numbers of subjects at the extremes of age at risk, as
has been pointed out (Risch, 2001), indicating that the actual
cumulative concordance exceeds 20%. If so, and if more than
77% of the cases in MZ twins represent heritable forms of disease,
the proportion of all breast cancer represented by heritable disease
exceeds 15%, and we have speculated on other grounds that it may
be even higher (Peto and Mack, 2000).
The pattern of occurrence in MZ and DZ co-twins is determined
by the mode of inheritance of disease. Any excess risk to a DZ twin
of a case is the result of sharing 50% of the genome and a common
early environment. Given a predominantly autosomal dominant
mode of inheritance, the increment of risk to an MZ co-twin would
be slightly less than double that to a DZ co-twin. This is because the
additional risk from sharing the other half of the genome would
produce the same incremental contribution as that from sharing
the ﬁrst half, and little, if any, added environmental risk would be
expected, because the commonality of MZ twins’ early environment
is probably only marginally greater than that of DZ twins. Since the
DZ twin of a case suffers a 70% increase in risk (overall relative risk
of 1.7 from Table 1), an increase of under 140% would be expected.
In fact, a relative risk of 4.4 (Table 1) indicates an increase of at least
340%, and the conﬁdence limits are such that the difference cannot
be explained by chance. A similarly large increase in risk attributable
to MZ status can be calculated from the Scandinavian twins study
(Lichtenstein et al, 2000). Such a large increment indicates that most
heritable breast cancers do not result from single autosomal domi-
nant alleles. While a recessive mode of inheritance cannot be
ruled out, that would seem an unlikely alternative, especially as a
cause of older cases (Cui et al, 2001b). It is more likely that a
substantial proportion of heritable breast cancer in both younger
and older women is polygenic, resulting from the interaction of
two or more coexisting alleles (Chen et al, 1995). In such a circum-
stance, a gene acting through a hormonal mechanism might only do
so in the presence of another existing genetic error in, for example, a
repair (tumour suppression) gene. Such a combination would
explain how a general defect of molecular repair might only produce
malignancy in one speciﬁc organ (Haber, 2000).
The pattern of occurrence in MZ twins also necessarily reﬂects
the mechanism of heritable breast carcinogenesis. The shorter than
expected intervals between co-twin diagnoses (Table 2) are similar
to the chronologic sequence of primary and contra-lateral breast
cancer diagnoses (Harvey and Brinton, 1985; Prior and Water-
house, 1978; Robbins and Berg, 1964; Storm and Jensen, 1986)
and, given the long latency, points to a roughly similar early age
at the time of a crucial causal event.
Moreover, to attain an incidence level over 1200:100000 before
age 30 (Table 1), the age-speciﬁc incidence of strictly heritable
disease must have risen very early and rapidly and must account
for nearly every early case. While the rate in MZ co-twins, based
on sporadic as well as heritable disease, stays virtually constant
(Figure 1), the population-based rate, largely from sporadic cases,
increases with age by an order of magnitude. The rate of heritable
disease therefore could not increase much over the same period
and may actually decline, another observation inconsistent with
causation by age-speciﬁc hormone accumulation. Thus alleles such
as those at CYP 17 (Henderson and Feigelson, 2000) are unlikely to
be the predominant determinants of heritable disease. Nor is the
polymorphism responsible for enzymatic conversion of androgens
into oestrogens (CYP19) likely to play a major role in heritable
disease, since this conversion takes place in fat cells, largely after
menopause, and too late to explain the early excess in risk.
Thus genetically determined high hormone levels are probably
not the predominant mechanism of heritable breast cancer carcino-
genesis. In fact the focus on high hormone levels as the phenotypic
expression of causal genes may be misplaced, because the familial
aggregation of hormone levels may not be even principally genetic
in origin. Lifestyle, including physical exercise (Bernstein et al,
1994), perinatal conditions (Ekbom et al, 1997, 2000), transient
episodes of disease-induced catabolism, and deﬁciencies in early
diet (Berkey et al, 2000; Willett, 1997), produce variations in age
at maturation, and probably underlie most of the change in risk
seen after migration (Shimizu et al, 1991) and economic develop-
ment (Miller and Bulbrook, 1986). Because families vary in the ease
and rapidity of acculturation and adaptation, age-speciﬁc hormone
proﬁles are likely to vary between them.
An alternative mechanism of heritable susceptibility, a geneti-
cally determined high cellular sensitivity to reproductive
hormones, is suggested by an animal model and does ﬁt the
observed pattern of occurrence. When treated with estradiol at a
standard dosage, certain rat strains rapidly develop breast cancer
almost without exception (Shull et al, 1997; Harvell et al, 2000).
Cancers resultant from a genetically induced enhancement of
human sensitivity to hormone exposure would be induced by the
ﬁrst major endogenous hormone exposure at puberty, resulting
in a pattern of risk like that observed among MZ twins (Table
1). Such sensitivity might result from polymorphic variation in
the human estrogen receptor (ER) gene (Andersen et al, 1994),
or by either overexpression of a transcription co-activator or
underexpression of a co-repressor (Ansick et al, 1997). Age-speciﬁc
breast sensitivity is precedented by radiogenic carcinogenesis which
is closely tied to early age at exposure (Aisenberg et al, 1997), and
adolescent soy intake during adolescence may preferentially reduce
breast cancer risk (Shu et al, 2001).
Twins comprise 2% of the North American population (Mack et
al, 2000) and suffer over 20000 cancer diagnoses each year. We
found no unusual cancer risk to twins as twins, since no signiﬁcant
or substantial increase in overall relative risk of cancer to the twin of
a case of another form of cancer appeared (Table 1). While there
seems to be no difference between breast cancer risk to the DZ twin
of a case and that to a non-twin sibling, the high risk to the MZ co-
twin of an early breast cancer, being twice that of a second primary
diagnosis, is of serious clinical concern. More frequent screening
procedures, chemoprophylaxis, and possibly prophylactic surgery,
with all corresponding pros and cons, should be discussed with each
such woman, as if she were a high risk gene carrier. Unfortunately,
twins rarely volunteer their twin status to their doctors. The ques-
tion of twinship should be posed to every patient when the
diagnosis of a serious familial disease is under consideration. Such
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Figure 2 Percentage of tumours ER+ by age at diagnosis: MZ cases from
breast cancer concordant and discordant pairs.
Heritable breast cancer in twins
TM Mack et al
298
British Journal of Cancer (2002) 87(3), 294–300 ã 2002 Cancer Research UKa practice will become even more clinically important as our know-
ledge of heritable risk and gene/environment interaction expands.
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